Archive ready

新型コロナウイルス治療薬の特例承認について｜厚生労働省

https://www.mhlw.go.jp/stf/newpage_19940.html

April 4, 2026 at 03:30 AM JST•The archive page, viewer, and downloads use this saved version.

April 4, 2026 at 03:30 AM JST·www.mhlw.go.jp

Saved page

Open the dedicated viewer to inspect the saved page with archive metadata pinned above it, similar to archive wrappers such as Web Gyotaku.

Original URLhttps://www.mhlw.go.jp/stf/newpage_19940.html

StartedApril 4, 2026 at 03:30 AM JST

This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.

The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.

About this pageAI generated

This page announces the special approval of a COVID-19 treatment drug by Japan's Ministry of Health, Labour and Welfare on July 19, 2021. Under Article 14-3 of the Pharmaceutical Affairs Law, Chugai Pharmaceutical Co., Ltd.'s drug "Ronapreve Intravenous Infusion Set" (generic names: casirivimab and imdevimab) received special approval for treating SARS-CoV-2 infection. The application was submitted on June 29, 2021.

Screenshot

The full page can be captured up to 15,000px in height so you can review the complete page layout when needed.